| Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation G Lebon, T Warne, PC Edwards, K Bennett, CJ Langmead, AGW Leslie, ... Nature 474 (7352), 521-525, 2011 | 1039 | 2011 |
| Muscarinic acetylcholine receptors as CNS drug targets CJ Langmead, J Watson, C Reavill Pharmacology & therapeutics 117 (2), 232-243, 2008 | 515 | 2008 |
| Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design M Congreve, SP Andrews, AS Doré, K Hollenstein, E Hurrell, ... Journal of medicinal chemistry 55 (5), 1898-1903, 2012 | 373 | 2012 |
| Progress in structure based drug design for G protein-coupled receptors M Congreve, CJ Langmead, JS Mason, FH Marshall Journal of medicinal chemistry 54 (13), 4283-4311, 2011 | 264 | 2011 |
| International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands A Christopoulos, JP Changeux, WA Catterall, D Fabbro, TP Burris, ... Pharmacological reviews 66 (4), 918-947, 2014 | 243 | 2014 |
| Characterisation of the binding of [3H]‐SB‐674042, a novel nonpeptide antagonist, to the human orexin‐1 receptor CJ Langmead, JC Jerman, SJ Brough, C Scott, RA Porter, HJ Herdon British journal of pharmacology 141 (2), 340-346, 2004 | 194 | 2004 |
| The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery N Robertson, A Jazayeri, J Errey, A Baig, E Hurrell, A Zhukov, ... Neuropharmacology 60 (1), 36-44, 2011 | 191 | 2011 |
| Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone ZA Hughes, KR Starr, CJ Langmead, M Hill, GD Bartoszyk, JJ Hagan, ... European journal of pharmacology 510 (1-2), 49-57, 2005 | 157 | 2005 |
| Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening CJ Langmead, SP Andrews, M Congreve, JC Errey, E Hurrell, ... Journal of medicinal chemistry 55 (5), 1904-1909, 2012 | 155 | 2012 |
| Differential GLP-1R binding and activation by peptide and non-peptide agonists X Zhang, MJ Belousoff, P Zhao, AJ Kooistra, TT Truong, SY Ang, ... Molecular Cell 80 (3), 485-500. e7, 2020 | 153 | 2020 |
| Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox CJ Langmead, A Christopoulos Trends in pharmacological sciences 27 (9), 475-481, 2006 | 142 | 2006 |
| G protein–coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus DM Riddy, P Delerive, RJ Summers, PM Sexton, CJ Langmead, ... Pharmacological reviews 70 (1), 39-67, 2018 | 135 | 2018 |
| Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors LT May, VA Avlani, CJ Langmead, HJ Herdon, MD Wood, PM Sexton, ... Molecular pharmacology 72 (2), 463-476, 2007 | 133 | 2007 |
| Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M1 receptor: direct pharmacological … CJ Langmead, VAH Fry, IT Forbes, CL Branch, A Christopoulos, ... Molecular pharmacology 69 (1), 236-246, 2006 | 127 | 2006 |
| Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1 CJ Langmead, NE Austin, CL Branch, JT Brown, KA Buchanan, ... British journal of pharmacology 154 (5), 1104-1115, 2008 | 125 | 2008 |
| New advances in targeting the resolution of inflammation: implications for specialized pro-resolving mediator GPCR drug discovery J Park, CJ Langmead, DM Riddy ACS pharmacology & translational science 3 (1), 88-106, 2020 | 108 | 2020 |
| Crystal structure of the M5 muscarinic acetylcholine receptor Z Vuckovic, PR Gentry, AE Berizzi, K Hirata, S Varghese, G Thompson, ... Proceedings of the National Academy of Sciences 116 (51), 26001-26007, 2019 | 87 | 2019 |
| Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy KA Bennett, B Tehan, G Lebon, CG Tate, M Weir, FH Marshall, ... Molecular pharmacology 83 (5), 949-958, 2013 | 85 | 2013 |
| Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor VA Avlani, CJ Langmead, E Guida, MD Wood, BG Tehan, HJ Herdon, ... Molecular pharmacology 78 (1), 94-104, 2010 | 80 | 2010 |
| Neurochemical Changes in LPA1 Receptor Deficient Mice – A Putative Model of Schizophrenia C Roberts, P Winter, CS Shilliam, ZA Hughes, C Langmead, PR Maycox, ... Neurochemical research 30, 371-377, 2005 | 80 | 2005 |
Arthur ChristopoulosMonash UniversityVerified email at monash.edu